Top Stories

IIT Madras-Incubated Plenome Raises INR 6.5 Cr to Scale Health Data Platforms

Image alt text

The round was led by Ovington Capital Partners (Luxembourg), with participation from UAE-based AADI and investor Manish Gandhi.

Plenome Technologies, incubated at IIT Madras, has secured INR 6.5 crore seed funding to scale its blockchain and AI-based platforms across healthcare and e-governance. 

The round was led by Ovington Capital Partners (Luxembourg), with participation from UAE-based AADI and investor Manish Gandhi.

Founded by Prof. Prabhu Rajagopal, Vijayaraja Rathinasamy, and Anirudh Varna, the startup focuses on secure, interoperable data systems. The funding will enable Plenome to expand its solutions across healthcare verticals, including its flagship products OrganEase, Ashwin, and BlockVote.

Commenting on the technology’s potential, co-founder Rathinasamy noted, “At Plenome, we are driven by the conviction that technology should be purposeful and inclusive, reaching those at the margins and delivering outcomes that are tangible, equitable, and sustainable.”

OrganEase, part of Plenome’s BlockTrack platform, is being trialed by a state-level transplant authority in South India. It is designed to manage sensitive organ donation data securely through blockchain infrastructure.

Ashwin, an AI-powered suite for electronic health data, is being piloted in dental practices. It supports voice-enabled data input in various Indic and international languages and is slated for rollout in cosmetic, eye care, and fertility domains.

Prof. Rajagopal said, “Our work improves access to healthcare in remote locations while enabling interoperability and insight generation based on structured medical records.”

The company is also building a distributed AI protocol that allows AI insights to be generated from verified, tamper-proof data logs.

More Articles By This Author


Show All
Newsletter

Signup for newsletter and stay updated

When digital health information is abundant but time is limited, access to curated, high-quality insights is more crucial than ever. Subscribe to our daily newsletter

Sign In

Sign In / Sign Up

Sign In & Stay updated with the latest news and analysis

+91